Moderna Stock Falls
Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...
While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...
10don MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback